KOSDAQBiotech & Pharma239610

Hlscience

₩6,500▲ 3.50%2026-11-18 close
Market Cap
₩35B
Turnover
₩200M
Volume
30K
Shares out.
5.4M
PER
—
PBR
0.4×
EPS
-₩2,205
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Revenue Turns Up From a Low, but Losses Persist

Revenue has risen for two straight quarters since its first-quarter 2026 low, but operating losses have continued for five consecutive quarters through the third quarter of 2026, and no profit turnaround has appeared yet.

  1. 1

    Revenue fell from KRW 52.8 billion in 2022 to KRW 16.7 billion in 2025, with three straight annual declines from 2023 to 2025.

  2. 2

    The 2025 operating loss widened to KRW 11.1 billion, with an operating margin of -66.2%, and the loss has grown each year since 2022.

  3. 3

    Quarterly revenue rose 17.1% and 7.7% quarter on quarter in the second and third quarters of 2026, yet third-quarter revenue was still down 22.0% year on year.

  4. 4

    The company launched the FAST OEM B2B platform for health functional foods in January 2026 and an AI and genetic data-based healthcare platform in June 2026.

  5. 5

    Losses attributable to owners of the parent over the last four quarters total KRW 11.2 billion, while total equity at end-2025 was KRW 82.8 billion against total liabilities of KRW 2.27 billion.

02

Business structure

Hlscience is a company centered on manufacturing and selling health functional foods, built on individually recognized functional ingredients it developed itself.

Its main products include pomegranate concentrate, milk thistle products and young barley, and a September 2019 company analysis described most of its revenue as coming from B2C home shopping channels, a mix that may have changed since.

In the third quarter of 2024, sales of young barley juice powder and diet product lines declined, shrinking the overall top line.

The company's business summary states that it became the first in Korea to enter CDMO business for individually recognized ingredients approved by the Ministry of Food and Drug Safety, offering a one-stop service.

In November 2025 it opened an online shop for its Skinmaster inner-beauty brand, and in January 2026 Skinmaster was listed on the Shopee e-commerce platform. Also in January 2026, it officially launched FAST OEM, a B2B integrated platform for health functional foods.

In June 2026 it released a hyper-personalized healthcare platform combining direct-to-consumer genetic testing, AI-based precision analysis, pharmacist consultation, and customized health food repackaging and supply.

The company describes this structure as a closed-loop ecosystem that links data analysis to product supply. Its stated strengths are individually recognized ingredients, original patents, in-house production facilities and a custom repackaging system.

Within the broader bio and pharma sector, its model differs from Samsung Biologics or Celltrion, which focus on biopharmaceutical contract manufacturing and biosimilars.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩3.5B-₩2.6B−76.0%
2025Q4₩2.4B-₩2.4B−101.6%
2026Q1₩2.1B-₩2.2B−105.2%
2026Q2₩2.5B-₩2.8B−111.6%
2026Q3₩2.7B-₩2.5B−93.4%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩52.8B-₩600M₩1.6B−1.1%1.5%4.3%
2023₩25.6B-₩4.7B-₩1.4B−18.3%−1.3%3.3%
2024₩17.7B-₩9.9B-₩7.9B−55.8%−8.3%3.3%
2025₩16.7B-₩11.1B-₩11.9B−66.2%−14.4%2.7%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-18

04

Earnings analysis

On an annual basis, revenue fell from KRW 52.8 billion in 2022 to KRW 25.6 billion in 2023 (down 51.5% year on year), KRW 17.7 billion in 2024 (down 31.0%) and KRW 16.7 billion in 2025 (down 5.4%).

Revenue declined for three straight years from 2023 to 2025, with 2022 the largest year and 2025 the smallest among 2022 to 2025.

The operating loss widened from KRW 604 million in 2022 to KRW 4.69 billion in 2023, KRW 9.86 billion in 2024 and KRW 11.1 billion in 2025, and the company has posted operating losses for four straight years from 2022 to 2025.

The operating margin moved from -1.1% in 2022 to -18.3% in 2023, -55.8% in 2024 and -66.2% in 2025. In the third quarter of 2024, lower sales of key products combined with a worse cost ratio to widen the loss.

Profit attributable to owners of the parent was KRW 1.59 billion in 2022, turned to a net loss of KRW 1.38 billion in 2023, and then recorded net losses of KRW 7.88 billion in 2024 and KRW 11.9 billion in 2025.

Net income including non-controlling interests, a different figure, was KRW 1.53 billion in 2022 and a net loss of KRW 11.9 billion in 2025, the same level as the parent-attributable loss that year.

The company said recognition of property, plant and equipment impairment losses after an asset impairment review raised both its pre-tax and net losses in 2025. Operating cash flow went from KRW 3.95 billion in 2022 to -KRW 1.96 billion in 2023, -KRW 3.59 billion in 2024 and -KRW 7.05 billion in 2025.

Quarterly revenue fell from KRW 3.45 billion in the third quarter of 2025 to KRW 2.35 billion in the fourth quarter (down 31.8% quarter on quarter) and KRW 2.13 billion in the first quarter of 2026 (down 9.3%), then recovered to KRW 2.5 billion in the second quarter (up 17.1%) and KRW 2.69 billion in the third quarter (up 7.7%).

Third-quarter revenue was still down 22.0% year on year.

Operating losses ran at KRW 2.62 billion, KRW 2.39 billion, KRW 2.25 billion, KRW 2.79 billion and KRW 2.51 billion across the five quarters from the third quarter of 2025 to the third quarter of 2026, and the third-quarter 2026 loss was narrower than a year earlier.

Net loss attributable to owners of the parent, however, was KRW 4.57 billion in the fourth quarter of 2025, the largest of the last five quarters, and KRW 2.3 billion in the third quarter of 2026, wider than a year earlier.

The four quarters from the fourth quarter of 2025 to the third quarter of 2026 total a net loss attributable to owners of KRW 11.2 billion.

05

Industry analysis

The points cited as differentiating this company in health functional foods are its individually recognized functional ingredients, original patents and in-house production facilities. On that basis the company positions itself as combining ingredient supply with customized product manufacturing.

However, revenue fell from KRW 52.8 billion in 2022 to KRW 16.7 billion in 2025, and the shrinkage appears to reflect the decline of home shopping sales, previously the core channel, along with lower sales of some key products.

According to the company, the domestic DTC genetic testing market keeps growing, yet most offerings remain limited to providing test results. The company aims to overcome that limit by combining testing, analysis, consultation and product supply on one platform.

The company also expects demand for prevention-focused healthcare to speed up adoption of personalized services by insurers, distributors and pharmacies.

Within the sector, this company differs from peers focused on drug pipelines or biopharmaceutical contract manufacturing, because product sales and ingredient-based business drive its results. Its earnings are therefore more sensitive to product demand and channel mix than to drug development timelines.

Strengths are ingredient differentiation and platform expansion, while the main weakness is that sales keep declining and the pace of channel transition could lag.

06

Outlook

The company's stated next step is to widen strategic partnerships with domestic and overseas distributors, insurers, pharmacies, corporate welfare platforms and healthcare companies after the platform's official launch. B2B partnership inquiries are being accepted through the official FAST OEM website.

On the B2C side, the Shopee listing and the Skinmaster online shop are cited as ways to diversify sales channels. Revenue rising for two consecutive quarters in the second and third quarters of 2026 can be read as an early sign of recovery.

Over the same period, however, the operating loss stayed at KRW 2.79 billion in the second quarter and KRW 2.51 billion in the third quarter, and the loss attributable to owners of the parent was KRW 2.3 billion in the third quarter.

Whether the new businesses have grown large enough to change the profit structure has therefore not yet been demonstrated. The next checkpoints are the operating margin and operating cash flow in the 2026 annual report, and how much revenue the platform and B2B partnerships add. The 2026 annual report is expected to be filed around March 2027.

07

Valuation

PER
—
PBR
0.4×
ROE
-13.8%
EPS
-₩2,205
BPS
₩14,912
Dividend per share
₩0

The price-to-earnings ratio (PER) cannot be calculated because the last four quarters show net losses, so earnings-based price comparisons do not apply. Asset-based measures therefore take center stage. The price-to-book ratio (PBR) sits well below 1x, meaning the market price is low relative to net asset value.

Total equity was KRW 82.8 billion at end-2025, of which KRW 82.6 billion is attributable to owners of the parent. Whether that asset value converts into earnings depends on whether operating losses continue and on one-off items such as the 2025 impairment loss.

The dividend yield is close to zero, so dividend income is not a prominent feature. According to the March 11, 2026 disclosure, the largest shareholder, CEO Lee Hae-yeon, and related parties hold 64.27%, which points to a high concentration of ownership.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-18

08

Bull factors

Platform expansion and B2B channels

With the FAST OEM launch in January 2026 and the healthcare platform in June 2026, the company is attempting to shift from a B2C-centered model toward business customers. It said it plans to expand partnerships with insurers, distributors, pharmacies and corporate welfare platforms.

Its individually recognized ingredients and in-house production facilities are presented as the basis for such partnerships.

Quarterly revenue up two quarters in a row

Second-quarter 2026 revenue of KRW 2.5 billion rose 17.1% quarter on quarter, and third-quarter revenue of KRW 2.69 billion rose a further 7.7%. The third-quarter 2026 operating loss of KRW 2.51 billion was narrower than the KRW 2.62 billion recorded in the third quarter of 2025. If the recovery from the first-quarter low continues, it could support a further narrowing of losses.

Capital base and insider share purchases

Total equity was KRW 82.8 billion at end-2025 with total liabilities of KRW 2.27 billion, a debt ratio of 2.7%. Equity was lower than the KRW 94.6 billion at end-2024, but the debt burden is low.

Open-market purchases by related party Lee Dong-hyun were disclosed from February to April 2026, with his stake reported at 26.95% in the April 2026 filing, and how investors read these purchases varies.

09

Bear factors

Revenue down three straight years

Revenue fell from KRW 52.8 billion in 2022 to KRW 16.7 billion in 2025, and 2025 revenue was down 5.4% year on year. In the third quarter of 2024, lower sales of young barley juice powder and diet product lines were cited as the reason for the shrinking top line. Third-quarter 2026 revenue was still 22.0% lower than a year earlier.

Continued losses and operating cash outflow

The 2025 operating loss was KRW 11.1 billion with an operating margin of -66.2%, and the loss has widened each year since 2022. Operating cash flow moved from KRW 3.95 billion in 2022 to -KRW 7.05 billion in 2025, turning from positive to negative. Losses attributable to owners of the parent over the last four quarters total KRW 11.2 billion.

Impairment and volatile quarterly losses

The company explained that impairment losses on property, plant and equipment following its 2025 asset impairment review raised pre-tax and net losses. The fourth-quarter 2025 loss attributable to owners of KRW 4.57 billion was the largest of the last five quarters.

The operating loss also widened to KRW 2.79 billion in the second quarter of 2026, so quarterly losses have swung considerably.

x

x

10

Risk factors

Portfolio transition

With home shopping and key product sales that once formed the revenue base declining, it is uncertain how much the new platforms and B2C channels can support revenue. How much the new businesses contribute to quarterly results is a point to examine in the next periodic report. If they fail to offset the decline in existing sales, the recovery in top-line growth could be limited.

Regulation and ingredient certification

Health functional foods are subject to the Ministry of Food and Drug Safety's ingredient certification and functional labeling rules. Changes to the scope of individually recognized ingredients or labeling rules could affect product lineups and sales.

The DTC business handles genetic data and must also comply with personal data protection rules, which could constrain the pace of expansion.

Financial capacity and cash burn

With operating and net losses continuing, total equity at end-2025 of KRW 82.8 billion was lower than at end-2024. The operating cash outflow widened to -KRW 7.05 billion in 2025 from -KRW 3.59 billion in 2024. If losses persist, the pace of equity decline and cash burn will become key indicators to watch.

11

What to watch next

  1. Around March 2027

    Filing of the 2026 annual report and the annual general meeting. The 2025 annual report was disclosed on March 6, 2026. This is where the 2026 operating margin, operating cash flow and the scale of new-business revenue can be checked together.

  2. Mid-May 2027

    First-quarter 2027 quarterly report. The first-quarter 2025 results were released on May 15 of that year. The checkpoints are whether quarterly revenue holds at or above the third-quarter 2026 level and whether the operating loss, around KRW 2.5 billion per quarter, narrows.

  3. Ad hoc disclosures from November 2026 onward

    Partnership announcements for the B2B platform. Watch whether agreements with insurers, distributors or pharmacies are disclosed and how their scale shows up in quarterly revenue.

  4. Ad hoc disclosures from November 2026 onward

    Share-ownership change filings by the largest shareholder and executives. Open-market purchases by Lee Dong-hyun were disclosed from February to April 2026. Any further changes would show shifts in the ownership structure and concentration.

12

Overall view

Hlscience's revenue fell from KRW 52.8 billion in 2022 to KRW 16.7 billion in 2025, and revenue rose in both the second and third quarters of 2026. Operating losses, however, have continued for five consecutive quarters through the third quarter of 2026.

The 2025 operating margin was -66.2%, and losses attributable to owners of the parent over the last four quarters total KRW 11.2 billion.

On the bull side, the B2B and platform expansion through FAST OEM and the healthcare platform, the recovery in second- and third-quarter 2026 revenue, and a low debt ratio of 2.7% stand out.

On the bear side, revenue has declined for three straight years, operating cash outflow has widened, the 2025 impairment loss and the wider fourth-quarter 2025 net loss weigh on results, and ownership is concentrated in the largest shareholder.

On valuation, PER cannot be calculated because of net losses, while PBR sits well below 1x. The asset base looks modest relative to net asset value, but earnings-based comparison is not possible at present.

The next checkpoints are the change in operating margin in the 2026 annual report, the size of quarterly losses in the first quarter of 2027, and how much revenue the new businesses contribute.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. comp.fnguide.com
  2. comp.fnguide.com
  3. comp.fnguide.com
  4. edaily.co.kr
  5. news.nate.com
  6. news.nate.com
  7. file.alphasquare.co.kr
  8. investing.com
  9. ssl.pstatic.net
  10. edaily.co.kr
  11. m.news.nate.com
  12. news.nate.com
  13. m.news.nate.com
  14. m.news.nate.com
  15. m.news.nate.com
  16. m.news.nate.com
  17. m.news.nate.com
  18. digitaltoday.co.kr

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis